Unknown

Dataset Information

Pharmacokinetics and Associated Efficacy of Emicizumab in Humans: A Systematic Review.


ABSTRACT:

Introduction

Emicizumab is an effective new treatment option for people with hemophilia A (PwHA). The approved dosing regimens are based on body weight, without the necessity for laboratory monitoring. This assumes a clear dose-concentration-response relationship, with acceptable variability due to factors other than body weight. To investigate this assumption, a systematic review on the pharmacokinetics (PK) and associated efficacy of emicizumab in humans was conducted.

Methods

The EMBASE, Pubmed and CENTRAL databases were systematically searched to November 2020 to identify studies on the PK data of emicizumab in humans. Data on the study, population, PK and efficacy (annualized bleeding rate of treated [joint] bleeds) were extracted and synthesized, and exposure effects m

SUBMITTER: Donners AAMT 

PROVIDER: S-EPMC8585815 | biostudies-literature | 2021 Nov

REPOSITORIES: biostudies-literature